Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2021 Sep 29.

Published in final edited form as: Menopause. 2021 Jul 26;28(10):1125–1129. doi: 10.1097/GME.0000000000001823

Table 3.

Associations of Estrogen Subtypes with Risk of Venous thromboembolism, stratified by the use of progestogen

	Incidence			Hazard Ratios
	Events	Person Years / 1000	Incidence Rate per 1000PY	Unadjusted (95%CI)	Age Adjusted(95%CI)	Fully Adjusted^a (95%CI)
Estrogen Only, n = 38800
CEE Oral	138	66.7	2.07	Ref	Ref	Ref
E2 Oral	26	13.3	1.96	0.94 (0.62-1.44)	1.05 (0.69-1.61)	1.06 (0.69-1.63)
E2 Transdermal	20	12.0	1.66	0.81 (0.51-1.29)	0.92 (0.57-1.47)	0.96 (0.59-1.54)
Estrogen + Progestogen, n = 12771
CEE Oral	27	18.4	1.47	Ref	Ref	Ref
E2 Oral	1	2.3	0.43	0.29 (0.04-2.11)	0.28 (0.04-2.10)	0.30 (0.04-2.22)
E2 Transdermal	2	1.3	1.56	1.03 (0.25-4.34)	1.02 (0.24-4.29)	1.06 (0.25-4.46)

^a

Adjusted for age, race, and BMI; stratified by previous use of HT

BMI = body mass index ; HT = hormone therapy ; CEE = conjugated equine estrogens ; E2 = estradiol